Clinical Trials

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance of < = 2.

- Confirmed diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) with documented
evidence of progression during or after the participant's last treatment based on the
Investigator's determination of the international myeloma working group (IMWG) (2016)
response criteria.

- Must have measurable disease with at least 1 of the following assessed within 28 days
of enrollment:

- Serum M-protein > = 0.5 g/dL (> = 5 g/L).

- Urine M-protein > = 200 mg/24 hours.

- In participants without measurable serum or urine M protein, serum free light
chain (FLC) > = 100 mg/L (10 mg/dL) (involved light chain).

- Must have received at least 2 or more lines of therapy, including a proteasome
inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody
(mAb).

- Must be naïve to treatment with B-cell maturation antigen (BCMA)-targeted therapy.

- Must be eligible to receive the Investigator's choice standard available therapy (SAT)
based on approved prescribing information, previous MM treatment history, and
institutional guidelines.

Exclusion Criteria:

- Clinically significant (per Investigator's judgment) drug or alcohol abuse within the
last 6 months.

- Clinically significant conditions such as but not limited to the following: renal,
neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary,
or hepatic disease within the last 6 months that would adversely affect the
participant's participation in the study.

- Central nervous system involvement of MM.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/29/2024. Questions regarding updates should be directed to the study team contact.